Resolutions at the Extraordinary General Meeting in BioInvent on July 12, 2022

Rhea-AI Summary

BioInvent International held an Extraordinary General Meeting on July 12, 2022, where it elected Natalie Berner and Nanna Lüneborg as new Board members. The Board will increase by two members, with annual fees for incoming members continuing as resolved by the previous Annual General Meeting. The fees will be paid on a pro-rata basis according to the duration of their service. The minutes of the meeting will be accessible on the company's website. BioInvent focuses on developing immuno-modulatory antibodies for cancer therapies, with several ongoing clinical trials.

Positive

• Election of two new Board members may enhance governance and strategic direction.
• BioInvent's ongoing clinical programs in Phase I/II trials indicate robust development in cancer therapies.

Negative

• None.

LUND, SWEDEN / ACCESSWIRE / July 12, 2022 / BioInvent International ("BioInvent") (STO:BINV) (Nasdaq Stockholm:BINV) Extraordinary General Meeting (the "EGM") today resolved to elect Natalie Berner and Nanna Lüneborg as new Board members.

The EGM resolved, in accordance with the Nomination Committee's proposal, to increase the Board of Directors with two members through new election of Natalie Berner and Nanna Lüneborg as Board members. The annual fees per Board member, as resolved by the Annual General Meeting, shall continue to apply. Fees are to be paid to incoming Board members pro rata in relation to the Board member's actual duty period.

The minutes from the EGM will be available on the Company's website, www.bioinvent.com.

About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase l/ll trials for the treatment of hematological cancer and solid tumors, respectively and a fifth program just initiating clinical development. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.

The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow us on Twitter: @BioInvent.

For further information, please contact:
Cecilia Hofvander
Senior Director Investor Relations
+46 (0)46 286 85 50
cecilia.hofvander@bioinvent.com

BioInvent International AB (publ)
Co. Reg. No.: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com

Attachments

Resolutions at the Extraordinary General Meeting in BioInvent on July 12, 2022

SOURCE: BioInvent International

View source version on accesswire.com:
https://www.accesswire.com/708265/Resolutions-at-the-Extraordinary-General-Meeting-in-BioInvent-on-July-12-2022

FAQ

What decisions were made during the EGM of BioInvent on July 12, 2022?

During the EGM, BioInvent elected Natalie Berner and Nanna Lüneborg as new Board members.

Who were the new Board members elected at BioInvent's EGM?

Natalie Berner and Nanna Lüneborg were elected as new Board members.

What is the significance of the new Board members for BioInvent?

The new Board members may enhance the company's governance and strategic direction.

How does BioInvent generate revenue?

BioInvent generates revenue from research collaborations, license agreements, and by producing antibodies for third parties.

What type of company is BioInvent?

BioInvent is a clinical-stage biotech company focusing on novel immuno-modulatory antibodies for cancer therapy.